SCHEMBL1015993

SCHEMBL1015993

COC(=O)c1cc(-c2ccc(F)cc2)ccc1N

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.55
ALDH1A1 P00352 5/20 0.55
HSD17B10 Q99714 4/20 0.55
HPGD P15428 4/20 0.55
MAPT P10636 3/20 0.55
GAA P10253 2/20 0.55
TSHR P16473 2/20 0.55
ALOX15 P16050 1/20 0.55
IKBKB O14920 2/20 0.55
SLC6A4 P31645 1/20 0.54
SLC6A3 Q01959 1/20 0.54
CFTR P13569 3/20 0.50
NPC1 O15118 1/20 0.49
CASP3 P42574 1/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
SENP8 Q96LD8 1/20 0.49
SENP7 Q9BQF6 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
GFER P55789 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29481401 1.00 KDM4E (0.55) KDM4EALDH1A1HSD17B10HPGDMAPT
SCHEMBL29543806 0.98 KDM4E (0.54) KDM4EALDH1A1HSD17B10HPGDMAPT
SCHEMBL7529190 0.90 KDM4E (0.66) KDM4EALDH1A1HSD17B10HPGDMAPT
SCHEMBL21857075 0.87 ALDH1A1 (0.58) KDM4EALDH1A1HSD17B10HPGDMAPT
SCHEMBL165608 0.86 ALDH1A1 (0.62) KDM4EALDH1A1HSD17B10HPGDMAPT
SCHEMBL21798946 0.86 ALDH1A1 (0.51) KDM4EALDH1A1HSD17B10HPGDMAPT
SCHEMBL21798893 0.86 KDM4E (0.54) KDM4EALDH1A1HSD17B10HPGDMAPT
SCHEMBL421466 0.85 IKBKB (0.65) KDM4EALDH1A1HSD17B10HPGDMAPT
SCHEMBL4264458 0.84 ABL1 (0.61) KDM4EALDH1A1HSD17B10HPGDMAPT
SCHEMBL11758709 0.83 KDM4E (0.72) KDM4EALDH1A1HSD17B10HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637451-B2 Amino quinazoline derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-05-26 US disclosed
US-12466820-B2 Amino quinazoline derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2025-11-11 US disclosed
EP-4251620-B1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARM SPA (IT) 2025-04-16 EP disclosed
CN-118239931-A As P2X3Aminoquinazoline derivatives of inhibitors 奇斯药制品公司 2024-06-25 CN disclosed
CN-114269432-B As P2X3Aminoquinazoline derivatives of inhibitors 奇斯药制品公司 2024-05-07 CN disclosed
US-20240025880-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-01-25 US disclosed
US-20240025880-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-01-25 US disclosed
US-20240025880-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-01-25 US disclosed
US-20230092892-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2023-03-23 US disclosed
US-20220227749-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHARLES RIVER LABORATORIES, INC. 2022-07-21 US disclosed
WO-2020239952-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2020-12-03 WO disclosed
WO-2020239951-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2020-12-03 WO disclosed
WO-2020239951-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2020-12-03 WO disclosed
US-20200148676-A1 PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS ONCOSTELLAE, S.L. (ES) 2020-05-14 US disclosed
EP-3632912-A1 PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS Oncostellae, S.L. (ES) 2020-04-08 EP disclosed
EP-3632913-A1 CARBOXYLIC ACID DERIVATIVES OF PYRIDOQUINAZOLINES USEFUL AS PROTEIN KINASE INHIBITORS Oncostellae, S.L. (ES) 2020-04-08 EP disclosed
US-20200079773-A1 CARBOXYLIC ACID DERIVATIVES OF PYRIDOQUINAZOLINES USEFUL AS PROTEIN KINASE INHIBITORS ONCOSTELLAE, S.L. (ES) 2020-03-12 US disclosed
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US disclosed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US disclosed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200148676-A1 PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS MAP4K2, MAP4K1, MAP4K3 KDM4E 1078/4885ALDH1A1 4264/4885HSD17B10 4415/4885
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 SERPINE1, SERPINB1, SERPINC1 KDM4E 4108/4885ALDH1A1 888/4885HSD17B10 1898/4885
US-20220227749-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 KDM4E 3667/4885ALDH1A1 1918/4885HSD17B10 4815/4885
US-12466820-B2 Amino quinazoline derivatives as P2X3 inhibitors P2RX3, P2RX5, P2RX1 KDM4E 3667/4885ALDH1A1 1918/4885HSD17B10 4815/4885
US-20200079773-A1 CARBOXYLIC ACID DERIVATIVES OF PYRIDOQUINAZOLINES USEFUL AS PROTEIN KINASE INHIBITORS MAP4K2, MAP3K1, MAP4K1 KDM4E 1110/4885ALDH1A1 2104/4885HSD17B10 3480/4885
US-20230092892-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 KDM4E 3667/4885ALDH1A1 1918/4885HSD17B10 4815/4885
US-20240025880-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 KDM4E 3667/4885ALDH1A1 1918/4885HSD17B10 4815/4885
US-12637451-B2 Amino quinazoline derivatives as P2X3 inhibitors P2RX3, P2RX1, P2RX7 KDM4E 4583/4885ALDH1A1 1206/4885HSD17B10 3799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.